OxyContin OP 80mg – The Complete Medical Guide

OxyContin OP 80mg is an abuse-deterrent, extended-release oxycodone formulation classified as a Schedule II controlled substance. This maximum-strength tablet is reserved for management of severe, around-the-clock pain in opioid-tolerant patients. The “OP” designation indicates it contains physical and chemical barriers to deter crushing, snorting, or injecting – though risks of misuse and addiction remain significant.

Oxycontin OP 80mg

OxyContin OP 80mg is a powerful prescription opioid used to manage severe, chronic pain that requires continuous, long-term treatment. Its extended-release formulation delivers up to 12 hours of consistent pain relief, making it ideal for patients dealing with conditions like cancer pain or major back pain. The active ingredient, oxycodone, works by altering the brain’s response to pain. Due to its high potency, OxyContin OP 80 mg must be taken exactly as prescribed by a healthcare provider to minimize the risks of misuse, addiction, and overdose. Always follow your doctor’s guidelines for safe and effective use.

Medical Uses & Indications

FDA-Approved Uses

 Severe chronic pain requiring continuous opioid therapy
 Cancer pain management in highly opioid-tolerant patients
 Pain uncontrolled by lower-dose opioids

Key Clinical Features

• Formulation: Abuse-deterrent extended-release
• Onset: 1-2 hours
• Duration: 12-hour controlled release
• Equianalgesic ratio: 80mg q12h ≈ 120mg oral morphine daily
• DEA Classification: Schedule II (Highest abuse potential)

Pharmacology & Mechanism

Neurochemical Action

• Full μ-opioid receptor agonist
• κ-opioid receptor partial agonist
• Sustained activation of pain modulation pathways

Abuse-Deterrent Properties

• Hard plastic coating resists crushing
• Viscous gel formation when dissolved
• Not completely abuse-proof (oral abuse still possible)

Dosing & Administration

Strict Eligibility Criteria

• Confirmed opioid tolerance: ≥160mg oral morphine equivalent daily
• Stable pain pattern (Not episodic/breakthrough)
• Failed trials of lower-dose opioids

Conversion Protocol

1. Calculate total daily morphine equivalent

2. Reduce by 25-50% (incomplete cross-tolerance)

3. Divide by 2 for q12h dosing

Critical Safety Notes

 Hospital initiation mandatory
 Must swallow whole (never cut/crush/chew)
 Requires dual prescriber verification
 Naloxone rescue kit mandatory

Safety Profile

Common Adverse Effects

• Severe constipation (universal)
• Nausea/vomiting (50-60%)
• Profound sedation
• Cognitive impairment

Black Box Warnings

 High potential for addiction and abuse
 Life-threatening respiratory depression
 Accidental ingestion can be fatal
 Concomitant CNS depressant danger

Risk Mitigation Strategies

Prescribing Safeguards

1. Specialist pain management consultation required

2. Triplicate prescription forms in most states

3. Weekly follow-ups for first 3 months

4. Random pill counts and UDS

Patient Safety Measures

• Biometric locked storage required
• Mandatory caregiver training
• Medication disposal system provided
• Absolute alcohol prohibition

Clinical Alternatives

For Severe Chronic Pain

• Xtampza ER (abuse-deterrent oxycodone)
• Methadone (For select patients)
• Fentanyl transdermal

Non-Opioid Options

• Intrathecal pump therapy
• Dorsal column stimulation
• Adjuvant medications

Special Population Considerations